|| List of recent Proliferation-related patents
|Method for initiating software update through version-aware content|
Systems and methods are disclosed for updating players that run, display, or otherwise use electronically-stored content. Information is included in the content that not only indicates the player version needed to play the content, but also the existence of a newer player version.
|Compositions and methods for restoring the stratum corneum and treating dermatological diseases|
The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to restore the stratum granulosum and stratum corneum and treat a dermatological disease, such as, for instance atopic dermatitis. More specifically it provides terpenes and terpenoids such as monoterpenoids, sesquiterpenes and norisoprenoids as ingredients that work to restore and thicken the stratum granulosum and stratum corneum and treat a dermatological disease.
|Malignant and non-malignant disease treatment with ras antagonists|
The present disclosure describes new inhibitors or antagonists of ras useful for the treatment of conditions resulting from ras-induced or mediated cellular processes, including cellular proliferation, differentiation, apoptosis, senescence, and survival. These cellular processes may be associated with a non-malignant or malignant disease, disorder, or pathological condition.
|Zcytor19 polynucleotides, polypeptides, antibodies and methods of use|
Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class ii cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo.
|Interventional medical device and manufacturing method thereof|
An interventional medical device and manufacturing method thereof. The interventional medical device comprises: a stent body (1); a surface of the stent body (1) being provided with a drug releasing structure (3), and drug in the drug releasing structure (3) being drug for suppressing proliferation of adventitial fibroblasts and a drug for suppressing proliferation of intimal and/or smooth muscle cells.
|Novel anti-ddr1 antibody having anti-tumor activity|
As a result of producing anti-ddr1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human ddr1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of ddr1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of ddr1 in cells, and (vi) an activity to decrease the expression level of tgf-β in cells..
|Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer|
This invention provides methods for preventing, reducing, delaying or inhibiting the proliferation and/or growth and/or metastasis of lung cancers and prostate cancer that express or overexpress cd22 by contacting the lung cancer cell or prostate cancer cell with an antigen binding molecule that binds to cd22 expressed on the surface of the cancer cell.. .
|Mesenchymal stem cells expressing tnf-alpha receptors|
Mesenchymal stem cells which express tnf-α receptor type i in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease..
|Compounds inhibiting galectin-1 expression, cancer cell proliferation, invasion, and tumorigenesis|
Disclosed herein are compositions comprising a galectin-1-targeting compound in a therapeutically effective composition for treating cancer. In an aspect, a galectin-1-targeting compound is otx-008.
|Method of treating mucoepidermoid carcinoma|
Imidazoquinolines, as set forth in formula (i), are useful for inhibiting growth or proliferation of mucoepidermoid carcinoma cells. The therapeutic and prophylactic treatments provided by this invention are practiced by administering to a patient in need thereof an amount of a compound of formula (i) that is effective to inhibit growth or proliferation of the mucoepidermoid carcinoma cells..
|Preparation of fibrin gel for use as implant system|
The present invention aims to generate a fibrin gel for cell proliferation and transport using the patient's own blood or compatible blood. The gel-preparation process consists in taking a quantity of blood from the patient, using sodium citrate as anticoagulant, separating off the citrated plasma by centrifugation, and resuspending the cells to be transported in the plasma.
|Methods and systems for treating cell proliferation disorders|
And a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.. .
|Apparatus, systems, and methods for providing offloading to an alternate network|
This disclosure relates to a system and method for offloading selected data to an alternate communication network. The offloading provides another route for selected packet traffic that can relieve the burden on a mobile operator's network, such as the backhaul and core networks.
|Methods and compositions for targeted polynucleotide modification|
A variety of methods and compostions are provided, including methods and compositions for targeted modification of a specific target site in a cell or organism, methods for integrating polynucleotides of interest, methods to assess promoter activity, directly select transformed organisms, minimize or eliminate expression resulting from random integration into the genome of an organism, such as a plant, remove polynucleotides of interest, combine multiple transfer cassettes, invert or excise a polynucleotide, silence a gene, and identify and/or characterize transcriptional regulating regions. The methods involve the introduction of a cell proliferation factor and a double-strand break-inducing enzyme into an organism..
The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
|4-aminoquinazoline derivatives and uses thereof|
The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on histone deacetylases, but also has stronger differentiation induction and anti-proliferative activities for certain tumor cells.
|3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh|
The invention is directed to a compound of formula (i) or a pharmaceutically acceptable salt thereof, wherein r1-r6 are defined herein. The invention is also directed to compositions containing a compound of formula (i) and to the use of such compounds in the inhibition of mutant idh proteins having a neomorphic activity.
|Compositions and methods for suppressing endometrial proliferation|
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (serm) therapy.
|Methods for isolating and using a subset of cd8 t-cells that are resistant to inhibitors|
Methods for identifying a subset of cd8 t cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain cd8 t cells expresses elevated levels of scin and/or pla2g4a, with an elevated level indicative of proliferation of the identified cd8 t cells.
|Assay for inhibitors of cip/kip protein degradation|
An assay and system compatible with high throughput screening (hts) that is capable of identifying inhibitors, such as small-molecule inhibitors, of the degradation of the cdk inhibitor p21, are described. The assay is based on the use of fusion protein comprising (i) a p2 polypeptide; and (i) a reporter protein linked to the c-terminal of said p21 polypeptide, wherein the fusion protein has a half-life that is similar to that of the p21 polypeptide.
|Method of applying etfb to abnormal proliferation of cell, and abnormal proliferation inhibitor|
Provided is a method for identifying and suppressing abnormal growth of fibroblasts at an early stage. Provided is a method for identifying the growth state of fibroblasts using as an index the level of expression of etfb (electron transfer flavoprotein beta subunit), comprising: judging, in cases where the level of expression of etfb is high, that there is a high probability that fibroblasts are abnormally growing; and judging, in cases where the level of expression of etfb is low, that there is a high probability that fibroblasts are normally growing.
|Methods and compositions for the detection of balanced reciprocal translocations/rearrangements|
Disclosed are methods and compositions related to the detection of balanced reciprocal translocations/rearrangements and determination of the location of said balanced reciprocal translocations/rearrangements. Also disclosed are methods and compositions relating to the diagnosis of a disease or condition associated with uncontrolled cellular proliferation by the detection of balanced reciprocal translocation/rearrangement.
|Methods and compositions for mesenchymal stem cell proliferation|
Provided is a method for increasing proliferation of mesenchymal stem cells. The method entails contacting the cells with 6-bromoindirubin-3′-oxime (bio).
|Method of treating inflammation using human immunosuppressive protein|
A method of treating inflammation by administering a therapeutically effective amount of a human immunosuppressant protein (hisp) to a subject is presented. The inventors have discovered a novel immunosuppressive protein purified from the supernatant of hnt cell culture.
|Antibody and antibody-containing composition|
For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom.
|Antibodies against the ectodomain of erbb3 and uses thereof|
The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of erbb3 receptor and inhibit various erbb3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated erbb3 and inhibiting egf-like ligand mediated phosphorylation of the receptor.
|Method for therapeutic angiogenesis|
The present invention relates to the e2epf ucp-vhl interaction and the uses thereof, more precisely a method for increasing or reducing vhl activity or level by regulating ucp activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of ucp activity is accomplished by any ucp activity inhibitor selected from a group consisting of a small interfering rna (rnai), an antisense oligonucleotide, and a polynucleotide complementarily binding to mrna of ucp, a peptide, a peptide mimetics and an antibody, and a low molecular compound.
|Compositions for proliferation of cells and related methods|
We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (skps)).
|Compositions and method for manipulating pim-1 activity in circulatory system cells|
The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase pim-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding pim-1, and methods for enhancing the regenerative potential of stem cells in the heart..
|Heteroaromatic compounds as pi3 kinase modulators and methods of use|
The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (pi3 kinases) and mtor, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans..
|Tissue engineering device and construction of vascularized dermis|
An inkjet printing method, system, and computer-usable tangible storage device to print cells and biomaterials for three-dimensional cellular scaffolds and engineered skin grafts are disclosed. The process simultaneously deposits living cells, nutrients, growth factors, therapeutic drugs along with biomaterial scaffolds at the right time and location.
|Methods of treatment directed to neointimal proliferation generated by endothelial shear stress patterns from drug-eluting bioresorbable vascular scaffold implantation|
Treatments of coronary heart disease including the effect of endothelial shear stress (ess) on neointimal formation following a bioresorbable vascular scaffold implantation are disclosed.. .
|Method for reducing tumors and transforming cancer cells|
This invention is related to a phenol-quinone therapy that shrinks tumors and transforms cancer cells. The therapy include four phases.
|Albumin production and cell proliferation|
The present invention provides short activating rna molecules which up-regulate albumin production. The present invention also provides methods of up-regulating albumin production, such methods involving the use of short activating rna molecules capable of increasing the expression of albumin.
|Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)|
Pyridine compounds effective in modulation stat3 and/or stat5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.. .
|Blockade of eosinophil production by toll-like receptors|
It has long been known that eosinopenia is observed during acute bacterial infection yet the mechanism remains undefined. Herein, we investigated the consequence of exposure to microbial products, specfically bacterial lipopolysaccharide (lps), on eosinophil production.
|Cancer tissue-derived cell mass and a process for preparing same|
Disclosed is a novel cell mass derived from a cancer tissue, which can reflect the in vivo behavior of a cancer cell correctly. Also disclosed is a process for preparing the cell mass.
|Skin care compositions containing combinations of natural ingredients|
Described herein are various natural ingredients for skin-related applications. Individual compounds provide beneficial effects for improved collagen production, fibroblast proliferation, antioxidant protection and free radical inhibition.
|Vaccines for preventing and treating alzheimer's disease|
Disclosed herein are vaccines comprising an amyloid beta antigen and a nucleic acid encoding the amyloid beta antigen, or a variant thereof. T cell proliferation can be inhibited and itreg cells can be stimulated in the subject administered the vaccine.
|Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor|
The present invention relates to an anti-angiogenic composition, and more particularly, to a pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor. The inventors of the present invention have confirmed that microrna-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis induced in a low oxygen environment.
|Pharmaceutical angiogenic composition including a microrna-382 activator|
The present invention relates to an angiogenic composition, and more particularly, to a pharmaceutical angiogenic composition including a microrna-382 activator. The inventors of the present invention have confirmed that microrna-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis.
|Humanized anti-hla-dr antibodies|
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
|Method of automatic management of a collection of images and corresponding device|
The proliferation of digital devices has favored an explosion of the amount of image data stored by a user, and it is quite easy for a user to end up with many image duplicates in the user's image library. Prior art solutions can still be optimized with regard to detection of duplicate images in data storage.
|Semipermeable medical pouches and their uses|
A novel process for bacterial production of nanocellulose hydrogel pouches for applications for cell therapy, cell encapsulation, cell delivery, cell proliferation and cell differentiation has been invented. The process is based on fermentation of bacteria producing nanocellulose in oxygen permeable mold interconnected with tubing with diameter less than 5 mm.
|Inhibition of cell proliferation|
The disclosed modulators of rb:raf-1 interactions are potent, selective disruptors of rb:raf-1 binding, with ic50 values ranging from 80 nm to 500 nm. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer.
|Radiolabeled nucleoside analogue, and preparation method and use thereof|
A radiolabeled nucleoside analogue is provided, which includes radioactive iodine 123i/131i, and a nucleoside analogue selected from a group consisting of cytidine, thymidine, uridine, and a derivative thereof. A method for preparing the radiolabeled nucleoside analogue, and a use thereof are further provided.
|Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis|
Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.. .
|Methods for heart regeneration|
Methods for heart regeneration are provided. The invention provided herein includes methods of modulating proliferation of cardiomyocytes using small molecules and micro rnas.
|Differentiation modulating agents and uses therefor|
The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (fgf) signaling pathway, especially the fgf-1 or fgf-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions..
|Hyaluronic acid based copolymers|
Hyaluronic acid (ha) conjugates or crosslinked has compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof..
|Regulation of energy metabolism and obesity by modulating a proliferation-inducing ligand (april) or april signaling|
Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as b-cell activating factor (baff) and a proliferation-inducing ligand (april), their receptors, and molecules that modulate the interactions between the ligands and receptors..
|Method for obtaining a multicellular spheroid|
The invention provides a method for producing a multicellular spheroid comprising injecting a cell suspension into a gel. The invention also provides a method of producing a gel comprising one or more multicellular spheroids, the method comprising injecting a cell suspension into a gel, as well as a gel obtainable by the method.
|Methods and compositions for vein harvest and autografting|
The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ecm) deposition. Surgical techniques typically employed for vein harvest—stretching the vein, placing the vein in low ph, solutions, and the use of toxic surgical skin markers—are shown here to cause injury.
|Compositions for the treatment of peripheral ulcers of various origins|
The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use..
|Microrna inhibition for the treatment of inflammation and myeloproliferative disorders|
The present disclosure relates to the finding that microrna-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microrna-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of cutl1, arntl, picalm, jarid2, pu.1, csflr, hiflα, sla, cepbβ, and bach1, and the like..